• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

达到筛查年龄上限后的间期癌风险:基于粪便免疫化学检测的结直肠癌筛查中的风险分层告知

Interval cancer risk after the upper age limit of screening has been reached: Informing risk stratification in FIT-based colorectal cancer screening.

作者信息

van Stigt Brenda J, Lansdorp-Vogelaar Iris, Spaander Manon C W, van Vuuren Anneke J, Dekker Evelien, van Kemenade Folkert J, Nagtegaal Iris D, van Leerdam Monique E, Toes-Zoutendijk Esther

机构信息

Department of Public Health, Erasmus MC University Medical Centre, Rotterdam, The Netherlands.

Department of Gastroenterology and Hepatology, Erasmus MC University Medical Centre, Rotterdam, The Netherlands.

出版信息

Int J Cancer. 2025 May 1;156(9):1783-1790. doi: 10.1002/ijc.35294. Epub 2024 Dec 19.

DOI:10.1002/ijc.35294
PMID:39697047
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11887016/
Abstract

Upper age limits are currently fixed for all fecal immunochemical test (FIT)-based colorectal cancer (CRC) screening programs. A risk-stratified upper age limit may be beneficial. Therefore, we assessed differences in interval CRC risk among individuals who had reached the upper age limit of screening (75 years). Individuals with a negative FIT (<47 μg Hb/g feces) in the final round of the Dutch CRC screening program were selected from the national screening database and linked to the national cancer registry to identify CRCs diagnosed within 24 months (interval CRCs). Survival analyses assessed whether sex and last fecal hemoglobin (f-Hb) concentration were associated with interval CRC risk. A multivariable logistic regression assessed whether sex, last f-Hb concentration and screening round were associated with stage distribution (early vs. late). Last f-Hb concentrations were considered detectable when they were >0 μg Hb/g feces. Among 305,761 individuals with a complete follow-up (24 months), 661 were diagnosed with interval CRC (21.6 per 10,000 negative FITs). Individuals with detectable f-Hb (15%) were 5 times more likely to be diagnosed with interval CRC than those without (HR 4.87, 95%CI: 4.19-5.65). Moreover, their cancers were more often detected at a late stage compared to individuals without detectable f-Hb (OR 1.45, 95%CI: 1.06-2.01). Our results show that interval CRC risk among individuals aged ≥75 differs substantially by last f-Hb concentration, indicating a uniform age to stop screening is suboptimal. Future research, taking into account multiple screening rounds and FIT results, should determine the optimal risk-stratified screening strategy.

摘要

目前,所有基于粪便免疫化学检测(FIT)的结直肠癌(CRC)筛查项目都设定了年龄上限。风险分层的年龄上限可能会更有益。因此,我们评估了达到筛查年龄上限(75岁)的个体之间间隔期结直肠癌风险的差异。从荷兰全国筛查数据库中选取了在荷兰CRC筛查项目最后一轮中FIT结果为阴性(<47μg血红蛋白/克粪便)的个体,并与国家癌症登记处进行关联,以确定在24个月内诊断出的CRC(间隔期CRC)。生存分析评估了性别和末次粪便血红蛋白(f-Hb)浓度是否与间隔期CRC风险相关。多变量逻辑回归评估了性别、末次f-Hb浓度和筛查轮次是否与分期分布(早期与晚期)相关。当末次f-Hb浓度>0μg血红蛋白/克粪便时,认为其可检测。在305,761名有完整随访(24个月)的个体中,661人被诊断为间隔期CRC(每10,000次FIT阴性中有21.6例)。f-Hb可检测的个体(15%)被诊断为间隔期CRC的可能性是f-Hb不可检测个体的5倍(风险比4.87,95%置信区间:4.19-5.65)。此外,与f-Hb不可检测的个体相比,他们的癌症更常被诊断为晚期(比值比1.45,95%置信区间:1.06-2.01)。我们的结果表明,年龄≥75岁个体的间隔期CRC风险因末次f-Hb浓度而有很大差异,这表明统一的停止筛查年龄并非最佳选择。未来的研究应考虑多次筛查轮次和FIT结果,以确定最佳的风险分层筛查策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f216/11887016/f935bc10c4f1/IJC-156-1783-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f216/11887016/f935bc10c4f1/IJC-156-1783-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f216/11887016/f935bc10c4f1/IJC-156-1783-g002.jpg

相似文献

1
Interval cancer risk after the upper age limit of screening has been reached: Informing risk stratification in FIT-based colorectal cancer screening.达到筛查年龄上限后的间期癌风险:基于粪便免疫化学检测的结直肠癌筛查中的风险分层告知
Int J Cancer. 2025 May 1;156(9):1783-1790. doi: 10.1002/ijc.35294. Epub 2024 Dec 19.
2
Factors associated with interval colorectal cancer after negative FIT: Results of two screening rounds in the Dutch FIT-based CRC screening program.阴性粪便免疫化学检测(FIT)后与结直肠癌间隔期相关的因素:荷兰基于 FIT 的 CRC 筛查计划中两次筛查轮次的结果。
Int J Cancer. 2023 Apr 15;152(8):1536-1546. doi: 10.1002/ijc.34373. Epub 2022 Dec 1.
3
Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.多次粪便免疫化学检测受试者的间期结直肠癌发病率。
Gastroenterology. 2017 Aug;153(2):439-447.e2. doi: 10.1053/j.gastro.2017.05.004. Epub 2017 May 5.
4
Personalized colorectal cancer screening: study protocol of a mixed-methods study on the effectiveness of tailored intervals based on prior f-Hb concentration in a fit-based colorectal cancer screening program (PERFECT-FIT).基于 FIT 基础结直肠癌筛查方案中既往 f-Hb 浓度的定制间隔的个性化结直肠癌筛查:基于效果的混合方法研究方案
BMC Gastroenterol. 2023 Feb 22;23(1):45. doi: 10.1186/s12876-023-02670-1.
5
Harm-to-Benefit Ratio of Fecal Immunochemical Test-Based Screening for Colorectal Cancer Given Prior Fecal Hemoglobin Concentrations.基于粪便免疫化学检测的结直肠癌筛查在既往粪便血红蛋白浓度情况下的危害与获益比
Clin Gastroenterol Hepatol. 2025 Mar;23(4):653-661.e3. doi: 10.1016/j.cgh.2024.08.041. Epub 2024 Oct 11.
6
Association Between Concentrations of Hemoglobin Determined by Fecal Immunochemical Tests and Long-term Development of Advanced Colorectal Neoplasia.粪便免疫化学检测血红蛋白浓度与结直肠高级别腺瘤长期进展的相关性。
Gastroenterology. 2017 Nov;153(5):1251-1259.e2. doi: 10.1053/j.gastro.2017.07.034. Epub 2017 Jul 29.
7
Effects of Increasing Screening Age and Fecal Hemoglobin Cutoff Concentrations in a Colorectal Cancer Screening Program.增加结直肠癌筛查计划的筛查年龄和粪便血红蛋白截断浓度的效果。
Clin Gastroenterol Hepatol. 2016 Dec;14(12):1771-1777. doi: 10.1016/j.cgh.2016.08.016. Epub 2016 Aug 24.
8
The second round of the Dutch colorectal cancer screening program: Impact of an increased fecal immunochemical test cut-off level on yield of screening.荷兰结直肠癌筛查项目第二轮:粪便免疫化学检测截断值提高对筛查效果的影响。
Int J Cancer. 2020 Aug 15;147(4):1098-1106. doi: 10.1002/ijc.32839. Epub 2020 Jan 9.
9
Impact of a higher fecal immunochemistry test cut-off on pathology detected in subsequent rounds of a colorectal screening program.更高的粪便免疫化学检测截断值对后续轮次结直肠筛查项目中检出的病理结果的影响。
Gastrointest Endosc. 2019 Mar;89(3):518-522. doi: 10.1016/j.gie.2018.08.015. Epub 2018 Aug 22.
10
Precision Colorectal Cancer Fecal Immunological Test Screening With Fecal-Hemoglobin-Concentration-Guided Interscreening Intervals.基于粪便血红蛋白浓度指导的间期进行精准结直肠癌粪便免疫化学检测筛查。
JAMA Oncol. 2024 Jun 1;10(6):765-772. doi: 10.1001/jamaoncol.2024.0961.

本文引用的文献

1
Colorectal Cancer Stage Distribution at First and Repeat Fecal Immunochemical Test Screening.首次和重复粪便免疫化学检测筛查中结直肠癌的分布阶段。
Clin Gastroenterol Hepatol. 2023 Dec;21(13):3424-3432.e2. doi: 10.1016/j.cgh.2023.07.028. Epub 2023 Aug 22.
2
Socioeconomic inequalities in interval colorectal cancer are explained by differences in faecal haemoglobin concentration and age: a register-based cohort study.社会经济不平等与结直肠间期癌的关系:基于注册的队列研究。
BMJ Open Gastroenterol. 2023 May;10(1). doi: 10.1136/bmjgast-2023-001113.
3
Improved use of faecal immunochemical tests for haemoglobin in the Scottish bowel screening programme.
提高粪便免疫化学试验在苏格兰肠道筛查计划中检测血红蛋白的应用。
J Med Screen. 2023 Dec;30(4):184-190. doi: 10.1177/09691413231175611. Epub 2023 May 25.
4
Faecal haemoglobin concentration predicts all-cause mortality.粪便血红蛋白浓度可预测全因死亡率。
Eur J Cancer. 2023 May;184:21-29. doi: 10.1016/j.ejca.2023.02.009. Epub 2023 Feb 15.
5
Colorectal cancer statistics, 2023.2023 年结直肠癌统计数据。
CA Cancer J Clin. 2023 May-Jun;73(3):233-254. doi: 10.3322/caac.21772. Epub 2023 Mar 1.
6
Personalized colorectal cancer screening: study protocol of a mixed-methods study on the effectiveness of tailored intervals based on prior f-Hb concentration in a fit-based colorectal cancer screening program (PERFECT-FIT).基于 FIT 基础结直肠癌筛查方案中既往 f-Hb 浓度的定制间隔的个性化结直肠癌筛查:基于效果的混合方法研究方案
BMC Gastroenterol. 2023 Feb 22;23(1):45. doi: 10.1186/s12876-023-02670-1.
7
Should we screen for colorectal cancer in people aged 75 and over? A systematic review - collaborative work of the French geriatric oncology society (SOFOG) and the French federation of digestive oncology (FFCD).我们是否应该对 75 岁及以上人群进行结直肠癌筛查?一项系统评价——法国老年肿瘤学会(SOFOG)和法国消化肿瘤学会联合会(FFCD)的合作工作。
BMC Cancer. 2023 Jan 5;23(1):17. doi: 10.1186/s12885-022-10418-5.
8
Factors associated with interval colorectal cancer after negative FIT: Results of two screening rounds in the Dutch FIT-based CRC screening program.阴性粪便免疫化学检测(FIT)后与结直肠癌间隔期相关的因素:荷兰基于 FIT 的 CRC 筛查计划中两次筛查轮次的结果。
Int J Cancer. 2023 Apr 15;152(8):1536-1546. doi: 10.1002/ijc.34373. Epub 2022 Dec 1.
9
Impact of time between faecal immunochemical tests in colorectal cancer screening on screening results: A natural experiment.粪便免疫化学试验在结直肠癌筛查中的时间间隔对筛查结果的影响:一项自然实验。
Int J Cancer. 2023 Apr 1;152(7):1414-1424. doi: 10.1002/ijc.34351. Epub 2022 Nov 21.
10
Initial Impact of National CRC Screening on Incidence and Advanced Colorectal Cancer.国家结直肠癌筛查对发病率及晚期结直肠癌的初步影响
Clin Gastroenterol Hepatol. 2023 Mar;21(3):797-807.e3. doi: 10.1016/j.cgh.2022.08.046. Epub 2022 Sep 16.